Onc.AI, a developer of AI-driven oncology clinical management software, has received breakthrough device designation from the U.S. Food and Drug Administration (FDA) for the company’s Serial CT Response Score (Serial CTRS) AI model.
Serial CTRS is an AI-based prognostic tool that uses deep learning to analyze CT scans and stratify patients into high- or low-mortality risk categories. This aims to help clinicians optimize treatment decisions and perform surveillance of patients with metastatic non-small cell lung cancer.
Onc.AI highlighted Serial CTRS at the Society for Immunotherapy of Cancer (SITC) annual meeting, highlighting a multi-institutional study where the tool improved the prediction of overall survival for patients receiving immunotherapy compared to traditional imaging assessment.